Implications of glucocorticoid therapy in idiopathic inflammatory myopathies.
about
Glucocorticoid receptor signaling in health and diseaseProphylactic and therapeutic functions of drug combinations against noise-induced hearing lossThe circadian clock in cancer development and therapyThe methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors at the myostatin and c-Met genes and regulates skeletal muscle atrophyA Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult SubjectsThe association between lean mass and bone mineral content in the high disease activity group of adult patients with juvenile idiopathic arthritis.Electrophysiologic and clinico-pathologic characteristics of statin-induced muscle injury.Overexpression of Glucocorticoid Receptor β Enhances Myogenesis and Reduces Catabolic Gene ExpressionThe vitamin d receptor and T cell function.Glucocorticoids increase skeletal muscle NF-κB inducing kinase (NIK): links to muscle atrophy.Does computed tomography-based muscle density predict muscle function and health-related quality of life in patients with idiopathic inflammatory myopathies?Glucocorticoid-associated osteoporosis in chronic inflammatory diseases: epidemiology, mechanisms, diagnosis, and treatment.Current pharmacological treatment of idiopathic inflammatory myopathies.Dexamethasone promotes long-term functional recovery of neuromuscular junction in a murine model of tourniquet-induced ischaemia-reperfusion.Dexamethasone Protects Against Tourniquet-Induced Acute Ischemia-Reperfusion Injury in Mouse Hindlimb.Identification of candidate genes and proteins in aging skeletal muscle (sarcopenia) using gene expression and structural analysis
P2860
Q26828358-84F2BF42-D8CB-475E-8F10-8C95973CF251Q28388403-C28BBCAE-73D5-4C00-A359-FD7F9A4E2828Q28390451-FF96186E-51E1-4D7C-8EE6-FA90554EBE65Q28592692-FDD4968B-7651-4136-9996-F1A638AF07ECQ33625958-DE45D814-CA9C-4D59-B57F-E4CC6B0B64FEQ35099938-3A1F386C-F2F5-41EE-BE2C-7D9467AAD83FQ36249326-9DCDEBBD-C0AE-4BBD-9F28-A6CE6AC13A34Q36667144-C9BDAC06-D762-44CA-AD8F-953E0A82B84FQ36935197-AA90B9DD-67FA-40C1-B04D-59B8C593C6F9Q37419006-E1E625CF-E837-4FAE-A71D-482D98AAA7B0Q37551973-DFA2E55A-9114-412A-A2C6-6E3758F29B11Q38227083-AD562675-27FF-48F3-8C3D-EA26FB65E32DQ38680762-723A7C04-84EA-466C-99CE-3BC49A3704F9Q51290274-1879E1F1-980F-46D6-BDFA-08BB75FB092EQ55107387-DE79F8C9-CD00-44E9-ACD9-A975B1A6B851Q58763087-A782C6DD-2E0C-4243-BA08-3A6547D3CC31
P2860
Implications of glucocorticoid therapy in idiopathic inflammatory myopathies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Implications of glucocorticoid therapy in idiopathic inflammatory myopathies.
@en
type
label
Implications of glucocorticoid therapy in idiopathic inflammatory myopathies.
@en
prefLabel
Implications of glucocorticoid therapy in idiopathic inflammatory myopathies.
@en
P2093
P2860
P356
P1476
Implications of glucocorticoid therapy in idiopathic inflammatory myopathies.
@en
P2093
Beatriz Y Hanaoka
Charlotte A Peterson
Craig Horbinski
Leslie J Crofford
P2860
P2888
P304
P356
10.1038/NRRHEUM.2012.85
P407
P577
2012-06-12T00:00:00Z
P6179
1014268334